NCT05337124Completed
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
Source: ClinicalTrials.gov · Last updated 24 Jun 2025
Brief summary (registry, in English)
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 229 (actual)
- First submitted
- 22 Mar 2022
- Start date
- 5 Apr 2022
- Primary completion date
- 31 Jan 2025
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Diseases
- Lupus (SLE)
- NCT number
- NCT05337124
What you commit to
- Study type: Observational
- Participants enrolled: 229
- From 5 Apr 2022 to the primary completion date, 31 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Off-label use (Use of LUPKYNIS outside of the FDA-approved US Prescribing Information)
Who the study is looking for
- Lupus nephritis (LN) confirmed by biopsy
- Initiating or have initiated treatment with commercial LUPKYNIS as per US approved Prescribing Information (PI)
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Site 00-05 Coordinator of this site? Confirm its status | South Gate | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.